Percentage body fat was 30% higher in women than in men not only at baseline, but also at final evaluation, due to the similar gain in fat mass in both sexes during HAART (Fig. 2).
There was a moderate correlation between serum leptin levels and body fat mass in both HIV-infected men and women at baseline (r = 0.64 and r = 0.68, respectively, P < 0.02 for both sexes). Positive correlations between the gain in serum leptin levels and in fat mass were noted only in women during HAART (r = 0.63, P < 0.03).
In contrast, baseline serum insulin levels did not correlate with baseline fat mass (r = 0.34 in men, r = 0.24 in women, P > 0.05 for both sexes), and the increase in serum insulin did not correlate with the gain in fat mass during therapy (r = 0.35 in men, r = 0.25 in women, P > 0.05 for both sexes).
Dyslipidaemia and asymptomatic atherosclerotic lesions are more frequent in HIV-positive patients than in healthy controls [17,26,27]. The risk to these patients of developing cardiovascular complications may increase further during long-term use of antiviral therapy .
As female sex protects from cardiovascular disease in HIV-seronegative subjects, we set out to study prospectively sex-differences in metabolic side-effects of a newly initiated HAART regimen, in particular to evaluate whether female sex is protective in this setting.
In good agreement with previous findings, HIV-infected patients had lower baseline levels of HDL than healthy age-matched controls  (Table 1), whereas levels of LDL (Table 1) and total cholesterol were not different from control values. The latter finding is possibly due to the relatively good immune and the adequate nutritional status of our HIV-patients, who were also free of opportunistic infections or wasting.
Hence, the baseline LDL : HDL ratio, an established indicator of cardiovascular risk, was higher in HIV-patients than in controls, and higher in HIV-infected men than HIV-infected women (Fig. 1). The less favourable lipid profiles in our male patients before the start of HAART mirror nicely what is seen in the general population, i.e. the well-known increased risk for cardiovascular disease in men as compared with women [9,29]. Thus, HIV-infected women seem to be naturally better ‘protected’ from the pro-atherogenic effects of HIV-infection per se than are men.
However, after initiation of a combined antiretroviral therapy, LDL : HDL ratios increased only in our female HIV patients (Fig. 1) due to increases in LDL (Table 2). As a consequence, the baseline sex difference in the LDL : HDL ratio finally disappeared (Fig. 1). Hence, women seemed to have ‘lost’ part of their natural protection from cardiovascular disease.
Baseline levels of serum triglycerides and insulin were similar between sexes as in a normal population, whereas serum leptin concentrations were trend-wise (> 30%) higher in female than in male patients. Although the magnitude of this sex difference was not significant, it was comparable to the degree of sex differences in leptin levels in a healthy population.
Antiretroviral therapy increased serum triglycerides, insulin and leptin levels predominantly in our female, and to a lesser extent in our male HIV patients (Fig. 2, Table 2). Even though we were not surprised to find rising leptin levels during HAART [30,31], we had not necessarily expected sharper increases in the female patients as compared with the male HIV-infected patients. Of note, the twofold increase in serum leptin levels in women (Fig. 2) is rather pronounced in view of animal studies, showing that induction of inflammation by lethal doses of endotoxin increased leptin levels only 2.5-fold .
Interestingly, HIV-infected men and women gained fat mass to comparable extents, but the increase in leptin and insulin levels was clearly more pronounced in the female patients (Fig. 2). Yet, we found a moderate correlation between the increase in leptin levels and the gain in fat mass in our female patients, but not in male patients. The moderate degree of correlation, however, indicates that the preferential increase in leptin levels in women was not solely dependent on the increase in fat mass. This is in line with previous findings indicating that circulating leptin levels do not correlate directly with weight changes in HIV-infected patients or reflect exclusively adipose tissue mass [33–35].
In view of several previous reports, peripheral insulin resistance could be an explanation for the elevations in serum insulin in these patients . Higher insulin concentrations may then have contributed to the increase in serum leptin levels, independently of body fat mass [37–39]. Finally, lower energy expenditure after successful antiretroviral treatment  may have been associated with an increase in leptin concentrations in this HIV-infected population .
Endothelial cell damage is present early in HIV infection, but the understanding of markers and mechanisms remains incomplete . It has been reported that HIV may infect vascular EC directly , and induce shedding of adhesion molecules from the cell surface, possibly due to oxidative stress . In addition, HIV and various opportunistic pathogens may exert indirect deleterious effects on EC, conceivably via pro-inflammatory cytokines.
Serum cE-selectin is a specific endothelial activation marker, which can indicate HIV-associated vascular inflammation , and/or atherosclerosis and the consecutive development of cardiovascular disease [18,52,53].
In this study, HIV-infected patients had higher baseline levels of cE-selectin than healthy controls confirming a previous cross-sectional study . HIV-infected male patients had almost 50% higher baseline levels of cE-selectin than female patients (Fig. 1) as would be expected from healthy controls [54,55]. The preserved sex differences in baseline cE-selectin levels in HIV infection may indicate that female sex protects against endothelial activation in HIV-infected individuals.
However, during HAART, serum cE-selectin levels declined in the male, but not in the female patients (Fig. 2), despite similar reductions in viral load. As a consequence, sex differences in cE-selectin were no longer apparent 6 months after initiation of HAART (P > 0.05, Fig. 2). This may be interpreted as evidence that HAART suppressed immunological/inflammatory processes in EC less effectively in female patients than in male patients.
A limitation of this study is that the question of whether the observed metabolic disturbances were related specifically to the use of PI could not be addressed in this setting. Indeed, previous studies on the association of metabolic changes with certain components of combinational regimens have produced inconsistent data. Whereas disturbances in lipid metabolism have been reported during HIV-therapy without PI , ‘switch studies’ have indicated that cholesterol and triglyceride levels fall when PI-containing therapy is discontinued . Furthermore, PI have been shown to increase concentrations of serum triglycerides and atherogenic lipoproteins even in healthy volunteers . Only very recently, in vitro experiments have shown a direct and dose-dependent influence of PI on insulin-stimulated glucose uptake in adipocytes .
As it cannot be ruled out completely that the stage of disease also influenced metabolic changes to a certain extent, only HIV and AIDS patients who were in very good clinical condition were enrolled in the study.
However, to answer more comprehensively the question of whether there is a cause and effect relationship between the use of PI-containing HAART and metabolic disturbances would require a comparison of (at least) two groups of patients, one receiving a PI-based regimen and the other receiving a non-NRTI in combination with two NRTI.
In summary, adverse metabolic effects of a HAART regimen were more pronounced in women than in men in this study. Female patients exhibited more distinct increases in serum levels of LDL, LDL : HDL, triglycerides, insulin and leptin decreased more in men than in women. Hence, female HIV-infected patients seem to loose part of their natural protection from atherosclerosis during antiretroviral therapy.
Further studies are necessary to determine whether these pro-atherogenic effects are related specifically to PI and whether in women non-NRTI-based regimens are as effective as PI-based regimens immunologically and virologically and with fewer adverse metabolic effects.
1. Martin JA, Smith BL, Mathews TJ, Ventura SJ. Births and deaths: preliminary data for 1998. Natl Vital Stat Rep 1999, 47: 1 –45.
2. Hammer SM, Squires KE, Hughes MD. et al
. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
N Engl J Med 1997, 337: 725 –733.
3. Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 1999, 13 (suppl 1): S49 –S59.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353: 2093 –2099.
5. Yanovski A, Miller KD, Kino T. et al
. Endocrine and metabolic evaluation of human immunodeficiency virus- infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999, 84: 1925 –1931.
6. Berthold HK, Parhofer KG, Ritter MM. et al
. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999, 246: 567 –575.
7. Behrens G, Dejam A, Schmidt H. et al
. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13: F63 –F70.
8. Walli R, Herfort O, Michl GM. et al
. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12: F167 –F73.
9. Bush TL, Barrett-Connor E, Cowan LD. et al
. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75: 1102 –1109.
10. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prevent Med 1991, 20: 47 –63.
11. Ickovics JR, Rodin J. Women and AIDS in the United States: epidemiology, natural history, and mediating mechanisms. Health Psychol 1992, 11: 1 –16.
12. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000, 85: 35 –41.
13. Periard D, Telenti A, Sudre P. et al
. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Circulation 1999, 100: 700 –705.
14. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84: 1932 –1937.
15. Pernerstorfer-Schoen H, Schindler K, Parschalk B. et al
. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 1999, 13: 2389 –2396.
16. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.MMWR
17. Constans J, Pellegrin JL, Peuchant E. et al
. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994, 24: 416 –420.
18. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997, 132: 151 –156.
19. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999, 27: 77 –81.
20. Lukaski HC, Johnson PE. A simple, inexpensive method of determining total body water using a tracer dose of D2O and infrared absorption of biological fluids. Am J Clin Nutr 1985, 41: 363 –370.
21. Shizgal HM. Validation of the measurement of body composition from whole body bioelectric impedance. Infusionstherapie 1990, 17 (suppl 3): 67 –74.
22. Kotler DP, Burastero S, Wang J, Pierson RN Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996, 64: S489 –S497.
23. Kautzky-Willer A, Fasching P, Jilma B, Waldhausl W, Wagner OF. Persistent elevation and metabolic dependence of circulating E-selectin after delivery in women with gestational diabetes mellitus. J Clin Endocrinol Metab 1997, 82: 4117 –4121.
24. Jilma B, Dallinger S, Hergovich N, Eichler HG, Richter V, Wagner OF. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules [see comments]. J Clin Endocrinol Metab 2000, 85: 1748 –1751.
25. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989, 52: 48 –60.
26. Constans J, Marchand JM, Conri C. et al
. Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study. Ann Med 1995, 27: 683 –685.
27. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis 2000, 11: 41 –46.
28. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet 1998, 351: 1958. 1958.
29. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.
Am J Med 1977, 62: 707 –714.
30. Paganelli R, Mezzaroma I, Mazzone AM, Pinter E, Aiuti F. Leptin levels in HIV-positive patients treated with HAART [letter]. AIDS 1999, 13: 2479. 2479.
31. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999, 13: 2251 –2260.
32. Grunfeld C, Zhao C, Fuller J. et al
. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996, 97: 2152 –2157.
33. Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly WG, Santiago JV, Landt M. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metab 1997, 46: 303 –305.
34. Ballinger A, Kelly P, Hallyburton E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clin Sci (Colch) 1998, 94: 479 –483.
35. Grunfeld C, Pang M, Shigenaga JK. et al
. Serum leptin levels in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996, 81: 4342 –4346.
36. Mulligan K, Grunfeld C, Tai VW. et al
. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23: 35 –43.
37. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996, 45: 988 –991.
38. Haffner SM, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL, Laakso M. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 1997, 21: 393 –399.
39. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996, 81: 4406 –4413.
40. Grinspoon S, Corcoran C, Miller K. et al
. Determinants of increased energy expenditure in HIV-infected women. Am J Clin Nutr 1998, 68: 720 –725.
41. Giltay EJ, Lambert J, Gooren LJ, Elbers JM, Steyn M, Stehouwer CD. Sex steroids, insulin, and arterial stiffness in women and men. Hypertension 1999, 34: 590 –597.
42. D'Agostino RB, Russell MW, Huse DM. et al
. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000, 139: 272 –281.
43. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999, 48: 426 –429.
44. De Mitrio V, De Pergola G, Vettor R. et al
. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism 1999, 48: 960 –964.
45. Loffreda S, Yang SQ, Lin HZ. et al
. Leptin regulates proinflammatory immune responses. FASEB J 1998, 12: 57 –65.
46. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13: 1231 –1238.
47. Leyva F, Godsland IF, Ghatei M. et al
. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998, 18: 928 –933.
48. Seigneur M, Constans J, Blann A. et al
. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost 1997, 77: 646 –649.
49. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986, 83: 7089 –7093.
50. Constans J, Seigneur M, Blann AD. et al
. Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction. Thromb Haemost 1998, 80: 1015 –1017.
51. Mandell BF, Calabrese LH. Infections and systemic vasculitis. Curr Opin Rheumatol 1998, 10: 51 –57.
52. Hwang SJ, Ballantyne CM, Sharrett AR. et al
. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96: 4219 –4225.
53. Blann AD, Farrell A, Picton A, McCollum CN. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb Res 2000, 97: 209 –216.
54. Jilma B, Eichler HG, Breiteneder H. et al
. Effects of 17 beta-estradiol on circulating adhesion molecules. J Clin Endocrinol Metab 1994, 79: 1619 –1624.
55. Blann AD, Daly RJ, Amiral J. The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Br J Haematol 1996, 92: 498 –500.
56. Saint-Marc T, Partisani M, Poizot-Martin I. et al
. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13: 1659 –1667.
57. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13: 805 –810.
58. Purnell JQ, Zambon A, Knopp RH. et al
. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14: 51 –57.
59. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275: 20251 –20254.